Learn what Wall Street already knows in our "Billion Dollar Secret" guide.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Revenues Fall at ViroPharma
ViroPharma Inc.’s third quarter 2012 adjusted earnings (including stock based compensation) of 3 cents per share were slightly above the Zacks Consensus Estimate of 2 cents but significantly lower than the year-ago earnings of 51 cents. The earnings decline was primarily attributable to lower revenues.
Quarterly revenues, which decreased 36.3% year over year to $91.0 million, missed the Zacks Consensus Estimate of $99 million. The decline in revenue was primarily attributable to decreased Vancocin sales due to generic competition. Quarterly Highlights
Cinryze sales increased 9.3% from the prior-year quarter to $83.7 million during the reported quarter, driven by higher demand. We note that ViroPharma has received US Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for industrial scale manufacturing for Cinryze. This industrial scale manufacturing will enable ViroPharma to increase Cinryze production capabilities.
In September 2012, the FDA informed ViroPharma that the company may continue with its clinical studies of the subcutaneous administration of Cinryze in combination with its partner, Halozyme Therapeutics’ ( HALO - Snapshot Report) recombinant human hyaluronidase enzyme (rHuPH20). The company plans to initiate a phase II study in the EU shortly. Data from the study are expected to be release in 2013.
We note that Vancocin sales plummeted 95% to $4 million in the reported quarter. The decline was attributable to the presence of generic vancomycin capsules in the US market.
Research and development (R&D) expenses declined 27.8% during the quarter to $16.5 million. However, the prior-year quarter included a $3 million and $6.5 million payments to Halozyme and Intellect Neurosciences , leading to the year-over-year R&D decline in the reported quarter. R&D increased 23.1% after adjustment of the one-time items. The increase was attributable to increased investment in Cinryze, Maribavir and Plenadren programs.
Selling, general and administrative (SG&A) expenses amounted to $44.3 million, up 41.3% from the prior-year quarter, due to costs related to the launch of Cinryze, Buccolam and Plenadren.
During the third quarter of 2012, ViroPharma repurchased 3.1 million shares for $80 million. The company has authorized a $200 million extension of the stock repurchase program. Outlook
Following the third quarter results, ViroPharma revised its guidance for 2012. The company has reduced its net product sales guidance to $425–$435 million (previous guidance: $450–$475 million). The decreased guidance was primarily due to an anticipated decrease in Vancocin revenues. The company maintained its US Cinryze sales guidance of $320–$335 million.
Further, the company continues to expect combined R&D and SG&A expenses in the range of $215–$235 million. Recommendation
We currently have a Neutral recommendation on ViroPharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.